The Canadian MS Working Group, under the aegis of the Canadian Network of MS Clinics, has released new recommendations on optimizing the treatment of multiple sclerosis (Freedman et al. Can J Neurol Sci 2020; online April 6, 2020; see link below). The paper updates the group’s prior recommendations published seven years ago (Freedman et al. Can J Neurol Sci 2013;40:307-323).
Neurology
AAN 2020 DAILY REPORT – THURSDAY, APRIL 30 EDITION
April 30, 2020The American Academy of Neurology (AAN) annual meeting, scheduled for April 25-May 1, 2020, was cancelled due to the COVID-19 pandemic. The following summarizes some of the new research that would have been presented at AAN 2020.
AAN 2020 DAILY REPORT – WEDNESDAY, APRIL 29 EDITION
April 29, 2020The American Academy of Neurology (AAN) annual meeting, scheduled for April 25-May 1, 2020, was cancelled due to the COVID-19 pandemic. The following summarizes some of the new research that would have been presented at AAN 2020.
AAN 2020 DAILY REPORT – TUESDAY, APRIL 28 EDITION
April 28, 2020The American Academy of Neurology (AAN) annual meeting, scheduled for April 25-May 1, 2020, was cancelled due to the COVID-19 pandemic. The following summarizes some of the new research that would have been presented at AAN 2020.
Siponimod – new data in SPMS
April 23, 2020Click here to take the SPMS survey
Siponimod, the selective sphingosine-1-phosphate (S1P) receptor modulator (S1P1,5), produces a sustained reduction in worsening disability for up to five years in patients with secondary-progressive MS (SPMS), according to data submitted to the American Academy of Neurology annual meeting (Kappos et al. AAN 2020; abstract S40.003).